Nervgen Pharma (NGEN) Non-Current Assets (2024 - 2026)

Nervgen Pharma (NGEN) posted quarterly Non-Current Assets of $288192.3 for Q1 2026, down 1.78% quarter-over-quarter from $293405.2 in Q4 2025.

Nervgen Pharma (NGEN) Non-Current Assets (2024 - 2026) Analysis & Trends

Nervgen Pharma (NGEN) has reported Non-Current Assets for 3 consecutive years, with $288192.3 the latest figure, recorded in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	14.88 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	23.28 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.96 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	5.15 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.96 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	938.60 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	468.65 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	18.06 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	6.80 Bn
10	Nervgen Pharma	161.78 Mn	161.78 Mn	-	275,626.10

Download Data